Tag: InflaRX

September 25, 2024 Off

Vilobelimab demonstrates significant improvement in reduction of draining tunnels

InflaRx N.V., a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today said that Vilobelimab demonstrates significant improvement in reduction of draining tunnels, total lesion count, International Hidradenitis Suppurativa Score 4 and the newly introduced modified-HiSCR

April 1, 2020 Off

InflaRx enrolls patient to test its antibody in COVID-19-induced pneumonia

By Dino Mustafić

German biopharmaceutical company InflaRx has enrolled the first patient into a randomized clinical trial investigating the safety and efficacy of IFX-1, the company´s monoclonal anti-C5a antibody, in patients with severe COVID-19-induced pneumonia.